siroquine (JP001) / Johnpro Biotech, HebaBiz Biotech - LARVOL DELTA

Draft genome sequence of Tetramitus sp. JP001. (PubMed, Microbiol Resour Announc) - "using Escherichia coli JC875 as prey. Despite their biological and ecological implications, members of the Tetramitus genus are not as extensively studied as other protists."

Journal

HebaBiz Biotech's anti-cancer drug candidate under development Siroquine (JP001) has been approved for IND clinical trials in the United States (PRNewswire) - “HebaBiz Biotech is pleased to announce…that the U.S. Food and Drug Administration (FDA) had granted clinical trial approval for Siroquine (JP001), an innovative anti-cancer drug under development. Such a clinical trial is to be conducted on newly diagnosed glioblastoma (GBM)...The clinical trial will be conducted in Taiwan, the United States and Mainland China.”

IND • Brain Cancer • CNS Tumor • Glioblastoma • Oncology

Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM (clinicaltrials.gov) - P2/3; N=288; Recruiting; Sponsor: Johnpro Biotech, Inc.; Not yet recruiting ➔ Recruiting; Trial completion date: Oct 2023 ➔ Apr 2025; Trial primary completion date: Oct 2023 ➔ Apr 2025

Clinical • Enrollment open • Trial completion date • Trial primary completion date